Literature DB >> 10749734

Altered membrane proteins and permeability correlate with cardiac dysfunction in cardiomyopathic hamsters.

Y Ikeda1, M Martone, Y Gu, M Hoshijima, A Thor, S S Oh, K L Peterson, J Ross.   

Abstract

A mutation in the delta-sarcoglycan (SG) gene with absence of delta-SG protein in the heart has been identified in the BIO14.6 cardiomyopathic (CM) hamster, but how the defective gene leads to myocardial degeneration and dysfunction is unknown. We correlated left ventricular (LV) function with increased sarcolemmal membrane permeability and investigated the LV distribution of the dystrophin-dystroglycan complex in BIO14.6 CM hamsters. On echocardiography at 5 wk of age, the CM hamsters showed a mildly enlarged diastolic dimension (LVDD) with decreased LV percent fractional shortening (%FS), and at 9 wk further enlargement of LVDD with reduction of %FS was observed. The percent area of myocardium exhibiting increased membrane permeability or membrane rupture, assessed by Evans blue dye (EBD) staining and wheat germ agglutinin, was greater at 9 than at 5 wk. In areas not stained by EBD, immunostaining of dystrophin was detected in CM hamsters at sarcolemma and T tubules, as expected, but it was also abnormally expressed at the intercalated discs; in addition, the expression of beta-dystroglycan was significantly reduced compared with control hearts. As previously described, alpha-SG was completely deficient in CM hearts compared with control hearts. In myocardial areas showing increased sarcolemmal permeability, neither dystrophin nor beta-dystroglycan could be identified by immunolabeling. Thus, together with the known loss of delta-SG and other SGs, abnormal distribution of dystrophin and reduction of beta-dystroglycan are associated with increased sarcolemmal permeability followed by cell rupture, which correlates with early progressive cardiac dysfunction in the BIO14.6 CM hamster.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10749734     DOI: 10.1152/ajpheart.2000.278.4.H1362

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  6 in total

1.  Delta-sarcoglycan gene therapy halts progression of cardiac dysfunction, improves respiratory failure, and prolongs life in myopathic hamsters.

Authors:  Masahiko Hoshijima; Takeharu Hayashi; Young E Jeon; Zhenxing Fu; Yusu Gu; Nancy D Dalton; Mark H Ellisman; Xiao Xiao; Frank L Powell; John Ross
Journal:  Circ Heart Fail       Date:  2010-10-29       Impact factor: 8.790

2.  Retrospective Study of Intercalated Disk Defects Associated with Dilated Cardiomyopathy, Atrial Thrombosis, and Heart Failure in BALB/c Mice Deficient in IL4 Receptor α.

Authors:  Alfonso S Gozalo; Patricia M Zerfas; William R Elkins; Richard L Gieseck
Journal:  Comp Med       Date:  2020-05-08       Impact factor: 0.982

3.  Simvastatin, atorvastatin, and pravastatin equally improve the hemodynamic status of diabetic rats.

Authors:  María J Crespo; José Quidgley
Journal:  World J Diabetes       Date:  2015-08-25

4.  Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats.

Authors:  Yoshitaka Iwanaga; Masahiko Hoshijima; Yusu Gu; Mitsuo Iwatate; Thomas Dieterle; Yasuhiro Ikeda; Moto-o Date; Jacqueline Chrast; Masunori Matsuzaki; Kirk L Peterson; Kenneth R Chien; John Ross
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

5.  Upregulation of the creatine synthetic pathway in skeletal muscles of mature mdx mice.

Authors:  Warren C McClure; Rick E Rabon; Hirofumi Ogawa; Brian S Tseng
Journal:  Neuromuscul Disord       Date:  2007-06-27       Impact factor: 4.296

Review 6.  Dysregulation of Calcium Handling in Duchenne Muscular Dystrophy-Associated Dilated Cardiomyopathy: Mechanisms and Experimental Therapeutic Strategies.

Authors:  Michelle L Law; Houda Cohen; Ashley A Martin; Addeli Bez Batti Angulski; Joseph M Metzger
Journal:  J Clin Med       Date:  2020-02-14       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.